Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

95 results about "Double stranded rna" patented technology

Compositions and methods for management of whitefly

The present disclosure is directed to controlling pest infestation by inhibiting one or more biological functions in an invertebrate pest. The disclosure discloses methods and compositions for use in controlling pest infestation by feeding one or more different recombinant double stranded RNA molecules to the pest in order to achieve a reduction in pest infestation through suppression of gene expression. The disclosure also discloses methods and compositions for targeted genome editing in the pest in order to achieve a reduction in pest infestation through disruption of protein activity. The disclosure is also directed to methods for making transgenic plants that express the double stranded RNA molecules and targeted genome editing constructs for use in protecting plants from pest infestation.
Owner:NATIONAL RESOURCES INSTITUTE +3

Double stranded RNA targeting proprotein convertase subtilisin kexin 9 (PCSK9) and methods of use thereof

PCT designated stage expiredWO2024263915A2Metabolism disorderPeptidasesSubtilisinProprotein Convertase Subtilisin/Kexin 9
The disclosure relates to isolated oligonucleotides comprising duplex regions targeting Proprotein convertase subtilisin kexin 9 (PCSK9), and delivery systems, kits and compositions comprising same, and methods of using same for inhibiting or downregulating PCSK9.
Owner:SANEGENE BIO USA INC

Complement component C3 iRNA compositions and methods of use thereof

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, Pemphigus, e.g., Pemphigus vulgaris (PV) and Pemphigus foliaceus (PF), and C3 glomerulopathy.
Owner:ALNYLAM PHARMACEUTICALS INC

IRNA compositions and methods for silencing angiotensinogen (AGT)

The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting an angiotensinogen (AGT) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., hypertension.
Owner:ALNYLAM PHARMACEUTICALS INC

Inhibin subunit beta e (INHBE) modulator compositions and methods of use thereof

The present invention relates to modulators, e.g., double stranded RNA (dsRNA) agents, antisense polynucleotide agents, antibodies, guideRNAs that effect ADAR editing, or guideRNAs that effect CRISPR editing, that modulate, e.g., inhibit, the expression and / or activity of inhibin subunit beta E (INHBE). The invention also relates to methods of using such modulators to inhibit expression and / or activity of INHBE and to methods of preventing and treating an INHBE-associated disorder, e.g., metabolic disorder, e.g., metabolic syndrome, in a subject.
Owner:ALNYLAM PHARMACEUTICALS INC

Engineered microalgae and use in aquaculture

PCT designated stage expiredWO2024238491A2ProtozoaUnicellular algaeBiotechnologyEngineering
The invention provides engineered microalgae comprising a double stranded RNA (dsRNA) that targets Enterocytozoon hepatopenaei, and methods of making and using the engineered microalgae in aquaculture.
Owner:REDUX BIO INC

COMPOSITIONS AND METHODS FOR DETECTING dsRNA

The present disclosure relates generally to antibodies and antigen-binding fragments that bind to double stranded RNA (dsRNA) and technologies for detection and / or quantification of dsRNA.
Owner:MODERNATX INC

IRNA compositions and methods for silencing complement component 3 (C3)

PendingUS20250019698A1Organic active ingredientsScreening processMotor neuropathyC3 Glomerulonephritis
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting a complement component C3 (C3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica (NMO), multifocal motor neuropathy (MMN), myasthenia gravis (MG), C3 glomerulonephritis, or systemic lupus erythmatosis.
Owner:ALNYLAM PHARMACEUTICALS INC

Affinity agents for RNA purification

PCT designated stageWO2025245419A2DNA preparationSingle-Stranded RNASingle strand
Provided are compositions, systems and methods for removal of double stranded RNA from a mixture utilizing affinity agents having high binding affinity and selectivity for double stranded RNA over single stranded RNA.
Owner:REPLIGEN CORP

Hepatitis b virus (HBV) dsrna agent compositions and methods of use thereof

The present disclosure relates to double stranded RNA agents targeting the hepatitis B virus (HBV) genome, and methods of using such agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection or HBV-associated disorder, e.g., chronic hepatitis B infection.
Owner:ALNYLAM PHARMACEUTICALS INC